Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.

By E. Lindmark, E. Diderholm, L. Wallentin, A. Siegbahn. Journal of the American Medical Association (JAMA), 2001

598 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/f68744a4b621885aa9574c85518bd2b373fbfada

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Tedgui
2. Z. Mallat
3. P. Ridker
4. Peter Libby
5. L. Melvin
6. R. Medzhitov
7. G. Hansson
8. S. Grundy

In Immunology

1. A. Tedgui
2. Z. Mallat
3. P. Ridker
4. Peter Libby
5. R. Medzhitov
6. G. Hansson

In Oncology

1. A. Tedgui
2. Z. Mallat
3. P. Ridker
4. R. Medzhitov

Citations in the corpus

• From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection (2016, background): “upstream IL-6 signaling has also been linked to plaque initiation and destabilization,(52,53) to microvascular flow dysfunction,(54) and to adverse outcomes in the setting of acute ischemia.(55) In contrast to CRP, IL-6 is highly upregulated at”
• Cytokines in atherosclerosis: pathogenic and regulatory pathways. (2006, methodology): “In the fast revascularization during instability in coronary artery disease (FRISC) II trial, IL-6 was an independent predictor of mortality among patients presenting with ACS, even when measurements with a hsCRP method were included in the analysis (403).”